Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Metoclopramide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 known ✓ | Q13639 | 5/20 | 0.98 |
| ▸ | HTR3A known ✓ | P46098 | 2/20 | 0.98 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.98 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.98 |
| ▸ | DRD3 | P35462 | 3/20 | 0.98 |
| ▸ | LMNA | P02545 | 3/20 | 0.98 |
| ▸ | HTR2B | P41595 | 2/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.98 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.98 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.98 |
| ▸ | HTR3B | O95264 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.98 |
| ▸ | MPO | P05164 | 1/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.98 |
| ▸ | DRD4 | P21917 | 1/20 | 0.98 |
| ▸ | HTR2A | P28223 | 1/20 | 0.98 |
| ▸ | HTR2C | P28335 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metoclopramide SCHEMBL205200 | 1.00 | RAB9A (1.00) | RAB9AHTR4CYP2D6CYP1A2ADRA2A | |
| Metoclopramide SCHEMBL30571110 | 1.00 | RAB9A (1.00) | RAB9AHTR4CYP2D6CYP1A2ADRA2A | |
| Metoclopramide SCHEMBL133509 | 0.99 | RAB9A (0.98) | RAB9AHTR4CYP2D6CYP1A2ADRA2A | |
| Metoclopramide SCHEMBL6263013 | 0.99 | RAB9A (0.98) | RAB9AHTR4CYP2D6CYP1A2ADRA2A | |
| Metoclopramide SCHEMBL18614363 | 0.99 | RAB9A (0.98) | RAB9AHTR4CYP2D6CYP1A2ADRA2A | |
| Metoclopramide SCHEMBL6569231 | 0.99 | RAB9A (0.98) | RAB9AHTR4CYP2D6CYP1A2ADRA2A | |
| Metoclopramide SCHEMBL5012583 | 0.99 | RAB9A (0.98) | RAB9AHTR4CYP2D6CYP1A2ADRA2A | |
| Metoclopramide SCHEMBL18629 | 0.99 | HTR4 (1.00) | RAB9AHTR4CYP2D6CYP1A2ADRA2A | |
| Metoclopramide SCHEMBL27855472 | 0.99 | HTR4 (1.00) | RAB9AHTR4CYP2D6CYP1A2ADRA2A | |
| Metoclopramide SCHEMBL28222039 | 0.99 | HTR4 (1.00) | RAB9AHTR4CYP2D6CYP1A2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105342997-B | A kind of metoclopramide dihydrochloride for injection and preparation method thereof | 山东齐都药业有限公司 | 2018-10-16 | — | — | CN | claimed |
| CN-105342997-A | Metoclopramide hydrochloride injection and preparation method thereof | SHANDONG QIDU PHARMACEUTICAL | 2016-02-24 | — | — | CN | claimed |
| EP-4706758-A2 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20240325487-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2024-10-03 | — | — | US | disclosed |
| CN-118706991-A | Method for detecting related substances of methoprene hydrochloride injection | 南京斯泰尔医药科技有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-11813304-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230277523-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| EP-3884935-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-114404588-A | Compounds and methods for inhibiting phosphate transport | 阿德利克斯公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-3972599-A1 | COMBINATION FOR LOWERING SERUM PHOSPHATE IN A PATIENT | Ardelyx, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| US-11246873-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-15 | — | — | US | disclosed |
| WO-2007053596-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007047978-A2 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007030697-A2 | MODULATION OF NEUROGENESIS BY HDAC INHIBITION | BRAINCELLS, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| WO-1997033621-A1 | PHARMACEUTICAL COMPOSITIONS | F.H. FAULDING & CO. LIMITED (AU) | 1997-09-18 | — | — | WO | disclosed |
| US-4176180-A | Pharmaceutical composition comprising erythromycin and metoclopramide and method of preparing same | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES (FR) | 1979-11-27 | — | — | US | disclosed |
| US-4146637-A | ANTIALLERGENS | LUDWIG MERCKLE K.G., CHEM. PHARM. FABRIK (DE) | 1979-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | HTR4 3498/4885HTR3A 3141/4885DRD2 4305/4885 |
| US-20240325487-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | HTR4 1928/4885HTR3A 991/4885DRD2 4720/4885 |
| US-11813304-B2 | Compounds and methods for inhibiting phosphate transport | SLC34A3, SLC34A2, SLC34A1 | HTR4 1928/4885HTR3A 991/4885DRD2 4720/4885 |
| US-20230277523-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | HTR4 3153/4885HTR3A 1919/4885DRD2 4876/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | HTR4 521/4885HTR3A 353/4885DRD2 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.